PT  - JOURNAL ARTICLE
AU  - See, Claudia
AU  - Grubman, Scott
AU  - Shah, Nisarg
AU  - Hu, Jiun-Ruey
AU  - Nanna, Michael
AU  - Freeman, James V.
AU  - Murugiah, Karthik
TI  - Healthcare Expenditure on Atrial Fibrillation in the United States: The Medical Expenditure Panel Survey 2016-2021
AID  - 10.1101/2024.10.30.24316453
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.30.24316453
4099  - http://medrxiv.org/content/early/2024/11/01/2024.10.30.24316453.short
4100  - http://medrxiv.org/content/early/2024/11/01/2024.10.30.24316453.full
AB  - Objectives To provide a contemporary nationally representative assessment of atrial fibrillation (AF) and atrial flutter (AFL) expenditures in the United States.Background AF prevalence is rising over time and management is evolving. However, there has been no contemporary national assessment of expenditures of AF.Methods Using Medical Expenditure Panel Survey (MEPS) 2016-2021 data, we identified individuals with AF or AFL using International Classification of Disease (ICD)-10 codes and reported total and categorized expenditures. Using two-part and gamma regression models, respectively, we estimated the incremental expenditures with AF for the entire population and for individuals with common coexisting comorbidities. Among individuals with AF, we identified characteristics associated with higher expenditures.Results Of a weighted surveyed population of 248,067,064 adults, 3,564,763 (1.4%) had AF. Mean age was 71.9 ± 10.6 years and 45.7% were female. Mean unadjusted annual total healthcare expenditure for individuals with AF was $25,451 ± $1,100 compared with $9,254 ± $82 for individuals without AF. The highest spending categories were inpatient visits ($7,975 ± $733) and prescriptions ($6,505 ± $372). AF expenditures increased over the study period by 11.1%. After adjustment, the incremental annual expenditure attributable to AF was $6,188 per person. Incremental expenditures with AF were highest for those with cancer ($11,967, 95% CI $4,410 - $19,525), while AF did not significantly increase expenditures in HF (-$2,756, 95% CI -$10,048 - $4,535). Modified Charlson Comorbidity Index of 1 or ≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditures.Conclusion AF is associated with substantial healthcare expenditures which are increasing over time. With changes in screening and management, expenditures need periodic reassessments.Introduction AF prevalence is rising, but contemporary national expenditure assessments are lacking.Methods Two-part and gamma regression models of MEPS 2016-2021 data (all-payer cross-sectional US survey) estimated AF effect on healthcare expenditures.Results Of 248,067,064 adults, 1.4% had AF, with mean age 72.1 years and 45.7% female. Mean unadjusted annual expenditure was $25,451 ± $1,100 ($9,254 ± $82 without AF). Incremental adjusted annual expenditure attributable to AF was $6,188. Modified CCI of 1 or ≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditure.Discussion AF expenditures are substantial and increasing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. See received support from the Yale School of Medicine 2023 Fellowship for Medical Student Research. Dr. Murugiah received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K08HL157727). Dr. Nanna reports research support from the American College of Cardiology (George F and Ann Harris Bellows Foundation), the Patient-Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging/National Institutes of Health (GEMSSTAR award: R03AG074067).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data were openly available prior to the study and continue to be available at: https://meps.ahrq.gov/mepsweb/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and materials are de-identified and publicly available online at https://meps.ahrq.gov/mepsweb/AFAtrial FibrillationCCICharlson Comorbidity IndexMEPSMedical Expenditure Panel SurveyNHEANational Health Expenditure AccountsUSUnited StatesAADAntiarrhythmic DrugAFAtrial FibrillationAHRQAgency of Healthcare Research and QualityASCVDAtherosclerotic Cardiovascular DiseaseCABANACatheter Ablation vs Antiarrhythmic Drug Therapy for Atrial FibrillationCCICharlson Comorbidity IndexCOPDChronic Obstructive Pulmonary DiseaseCPIConsumer Price IndexDOACDirect-Acting Oral AnticoagulantsEDEmergency DepartmentFPLFederal Poverty LineGEDGeneral Educational DevelopmentHFHeart FailureHSHigh SchoolMEPSMedical Expenditure Panel SurveyNCHSNational Center for Health StatisticsNHEANational Health Expenditure AccountsNHISNational Health Interview SurveyOROdds RatioSDStandard DeviationUSUnited StatesIQRInterquartile Range